Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is reporting third quarter financial results on Thursday 29th October 2020, after market close.
According to analysts surveyed by Thomson Reuters, VRTX is expected to report 3Q20 income of $ 2.34 per share from revenue of $ 1484.99 million.
For the full year, analysts anticipate top line of $ 6019.24 million, while looking forward to income of $ 9.84 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 5,700.00 million ~ $ 5,900.00 million
Click Here For More Historical Outlooks Of Vertex Pharmaceuticals Incorporated
Previous Quarter Performance
Vertex Pharmaceuticals Incorporated recorded income for the second quarter of $ 2.61 per share, from the revenue of $ 1,524.00 million. The quarterly earnings gained 107.14 percent while revenues gained 61.91 percent compared with the same quarter last year.
According to street consensus, VRTX was expected to report 2Q20 income of $ 2.07 per share from revenue of $ 1385.48 million. The bottom line results beat street analysts by $ 0.54 or 26.09 percent, at the same time, top line results outshined analysts by $ 138.52 million or 10.00 percent.
Stock Performance
Shares of Vertex Pharmaceuticals Incorporated traded low $ -3.85 or -1.81 percent on Wednesday, reaching $ 208.34 with volume of 2.22 million shares. Vertex Pharmaceuticals Incorporated has traded high as $ 214.24 and has cracked $ 208.25 on the downward trend
According to the previous trading day, closing price of $ 208.34, representing a 9.26 % increase from the 52 week low of $ 194.20 and a 30.67 % decrease over the 52 week high of $ 306.08.
The company has a market capital of $ 54.27 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 19th October 2020, maintained by Morgan Stanley at Equal-Weight rating, with $ 249.00 target price.
- On 15th October 2020, maintained by SVB Leerink at Market Perform rating, with $ 267.00 target price.
- On 13th October 2020, maintained by Morgan Stanley at Equal-Weight rating, with $ 281.00 target price.
Conference Call
Vertex Pharmaceuticals Incorporated will be hosting a conference call at 4:30 PM eastern time on 29th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.vrtx.com
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-659 and VX-445 that are Phase III clinical trials; VX-121, a cystic fibrosis transmembrane conductance regulator corrector that is in Phase I/II clinical trial; VX-150, an inhibitor that is in Phase IIb clinical trial for acute pain; CTX001 that is in Phase I/II clinical trial for the treatment of beta-thalassemia and sickle cell diseases; and a novel drug candidate, which is in Phase I clinical trial for the treatment for alpha-1 antitrypsin deficiency.
